American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
August 12, 2022
Earnings Call Speaker Segments
Stephanie Prince
executiveThanks, Sarah, and I appreciate all of you being with us today. Prior to handing things over to management, I'd like to offer these comments regarding forward-looking statements. Please be aware that a number of things that might be said during this conference call regarding the company's future expectations, plans and prospects are forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from what those forward-looking statements indicate, owing to a range of important factors, among them those addressed in the company's SEC filings. That covers the company's quarterly report on Form 10-Q covering the 3-month period that closed on March 31, 2022, the annual report on Form 10-K covering the year that closed on December 31, 2021, and the definitive proxy statement for the Annual Meeting of Shareholders held on June 21, 2022. The company undertakes no obligation to update the information in this conference call. I'd now like to hand the call over to Ray Stachowiak, CEO of AMS. Ray?
Ray Stachowiak
executiveThank you, Stephanie, and good morning to all, plus a good afternoon to those of you joining from the east coast. We appreciate you being with us for the conference call covering our 2022 second quarter earnings. I'll start things off with a few opening comments, and after that I'll hand things to Alexis Wallace, who serves as our Chief Accounting Officer, to walk through the financial review. Craig Tagawa, our President, COO and CFO, will then give an operational review of the results. Once their prepared remarks are finished, we'll take your questions. AMS enjoyed a very strong second quarter. Revenue came in at $5 million, which is 12.5% above the prior year and marks the best top line we've seen since the third quarter 2019, 3 years back. Net income hit $0.5 million, the strongest figure since the fourth quarter of 2017, more than 4 years ago. Craig and Alexis will share more detail in a few minutes. We've also been achieving excellent sequential improvement, extending the prior quarter's performance for 4 quarters in a row now. During the third quarter of 2021, net income was $33,000, or $0.01 per share. In the fourth quarter of 2021, net income was $219,000, or $0.04 per share. For the first quarter 2022, net income came to $269,000, or $0.04 per share. And in the second quarter, we nearly doubled that, reaching $497,000, or $0.08 per diluted share. These results came from the post-COVID rebound in volumes, better average reimbursement for both proton beam radiation therapy and Gamma Knife, and nearly as importantly, enhancements to our operating structure. Those have included strengthening our balance sheet, refinancing our debt at lower interest rates, and cutting our costs at every level we could, including shrinking our corporate office. Our team has worked diligently to achieve these goals, which mostly happened during the pandemic, when volumes for our cancer treatments were low, which amplified our high fixed cost structure. We've been broadening our radiation therapy product offerings, and we're now positioned to boost our investment in sales and marketing initiatives to drive future growth. Our dedication is underscored by the recent hiring of AMS's new Head of Sales, Tim Keel, a seasoned executive in our industry whom both Craig and I have known for many years. Tim brings deep experience and strong industry relationships, and we're confident in his ability to build AMS' sales momentum. Our better results have grown our cash balances, and we closed the second quarter with $12 million in cash, or roughly $1.91 per share, based on 6.3 million fully diluted shares at June 30, 2022. That compares with our shareholders' equity, excluding the noncontrolling interest in subsidiaries, which stood at $20.8 million, or $3.32 per diluted share, also at June 30, 2022. With the strong foundation we've built, the growing investment in sales and marketing, and our substantial resources to partner on deals, such as the joint venture we're working to open in Puebla, Mexico in early 2023. Our view is that AMS sits in a strong spot to keep growing and remain profitable over the long run. At this point I'll hand things over to Alexis, who will walk through the financial review for the second quarter. Alexis?
Alexis Wallace
executiveThank you, Ray, and good afternoon, everyone. Before diving into my prepared remarks, I'd like to point you toward the earnings press release covering our second quarter of 2022, which was issued after yesterday's market close. If you'd like a copy, it's available at ashs.com on our website, accessible through the Investor tab within the Press Releases section. So with that, let's move on to how we performed in Q2. During the three months concluding June 30, 2022, revenue increased 12.5%, arriving at $5.034 million, compared with $4.476 million during the second quarter of 2021. Now shifting to Florida and Orlando Health, where our proton therapy system is operational: revenue for Q2 there jumped 49%, arriving at $2.308 million. That's measured against $1.549 million during the equivalent quarter of 2021. Proton therapy fractions across the quarter came to 1,324, which is 19.4% higher than the 1,109 fractions recorded in Q2 of 2021. Over on the Gamma Knife side, revenue declined 6.9%, settling at $2.726 million in this year's second quarter, versus $2.927 million 12 months earlier. Gamma Knife procedures dropped 10.9%, finishing at 335 during Q2 of 2022, compared with 376 across the same span of 2021. In Q2 2022, our gross margin climbed 29.9%, reaching $2.088 million—equivalent to 41.5% of revenue. Gross margin during Q2 2021 stood at $1.607 million, or 35.9% of revenue. Selling and administrative costs rose 5.1% across the three months, amounting to $1.146 million. In the comparable period a year before, those costs totaled $1.090 million. Interest expense declined 9.7%, landing at $149,000. It had been $165,000 during last year's matching period. Operating income for the second quarter came in at $793,000. Set against $352,000 in Q2 2021, that marks a 125% gain. Income tax expense during the second quarter rose by $248,000, while last year's second quarter produced a tax benefit of $24,000. Three factors drove that increase: stronger profits in the current period, adjustments reversing provisions tied to foreign income tax filings made this period, and permanent differences in domestic taxes. Looking at the remainder of this year, we expect the tax rate to stay elevated. American Shared Hospital Services posted net income of $497,000 for the second quarter of 2022, equal to $0.08 per diluted share. Compare that with a net loss of $87,000, or $0.01 per diluted share, in the matching quarter of 2021. Embedded within the 2021 second quarter was a pretax loss of $401,000 stemming from debt extinguishment. During Q2 of 2021, American Shared Hospital Services recorded net income attributable to the company—following exclusion of the net impact from debt extinguishment and after accounting for noncontrolling interest and income taxes totaling $244,000—of $157,000, or $0.03 per diluted share. The fully diluted weighted average common shares outstanding totaled 6,281,000, versus 5,802,000 and 5,802,000 for the second quarters of 2022 and 2021, respectively. Separately, we recorded $1.9 million. On a non-GAAP basis, adjusted EBITDA came in at $2.129 million for the second quarter of 2022, up 16.4% from $1.829 million in the comparable quarter of 2021. That improvement included $1.9 million in operating gains. When we closed the books on June 30, 2022, cash, cash equivalents and restricted cash stood at $11.967 million, which is higher than the $8.263 million we reported at December 31, 2021. Shareholders' equity was $25.337 million as of June 30, 2022, versus $24.239 million at December 31, 2021. With that, I'll turn it over to Craig, who can take us through the operational side of how Q2 went. Craig?
Craig Tagawa
executiveThanks, Alexis, and good afternoon to all of you. As Alexis said, we brought in $5 million in total revenue for the second quarter, which is up 12.5% compared with the same quarter a year ago. This carried forward the upward revenue trajectory that began in Q4 of 2021, when we posted $4.7 million. That was the top revenue figure for the year, and it continued into Q1 with $4.8 million reported. For the proton therapy system in Florida, second quarter 2022 revenue rose 49.0% to $2.3 million, thanks to greater volumes and higher average reimbursement stemming from a larger share of commercial payers. Total proton therapy fractions grew 19.4% to 1,324. This increase largely reflected weaker results in the prior year's second quarter caused by the pandemic's impact. Gamma Knife revenue fell 6.9% to $2.7 million. That drop came from fewer procedures, partly offset by higher average reimbursement. The reimbursement gain was fueled by a rise in the average rate at the company's retail sites, resulting from a favorable shift in payer mix toward more commercial payers. For same centers in operation, excluding the 2 Gamma Knife contracts that expired, 1 each in the first and fourth quarters of 2021, revenue declined 7% versus those same centers in the comparable period of the previous year. Gamma Knife procedures dropped by 10.9% to 335 in the second quarter. This was mainly attributable to the expiration of the 2 contracts I just referenced. If you exclude those 2 expired contracts, Gamma Knife volumes for same centers in operation fell 6% compared with Gamma Knife volumes at those same centers in the same period of the prior year, which we consider a normal cyclical fluctuation. Gross margin climbed 29.9% in dollars to $2.1 million. The gross margin percentage widened 560 basis points to 41.5% of revenue, versus 35.9% in the second quarter of 2021. We achieved this gain even with higher international operating costs caused by greater volumes at those locations, and it stands among the highest levels we have ever recorded. Selling and administrative costs rose 5.1% to $1.1 million compared with last year's second quarter, driven by higher sales, legal and related fees tied to new business opportunities such as the Puebla, Mexico project we announced in April. At our international locations, the Icon upgrade at Gamma Knife Center Ecuador is still slated for installation late this year while we await the required regulatory approvals; it will be one of only a few Gamma Knife Icon units across all of South America. We will also put a new LINAC accelerator at our joint venture in Puebla, Mexico, which is expected to open in early 2023, subject to licensing and regulatory approvals. To wrap up, with our stronger balance sheet, better results and resources, and a renewed emphasis on sales and marketing, we are excited about what lies ahead for AMS; that brings the formal portion of our presentation to a close. Sarah, at this point we want to hand things back over to you and begin the question-and-answer portion.
Tony Kamin
analystNice quarter — congratulations. Raymond, I came in late, so apologies if this was already covered and I'm asking again. Could you expand a bit on what you just described — the refreshed emphasis on sales and marketing? I believe I raised this on your prior quarterly call as well, but could you speak to how the pipeline is developing? Is it growing? Are talks with any possible partners moving forward? In other words, how should we think about the likelihood of bringing additional products to market?
Ray Stachowiak
executiveThanks, Tony. I'm glad you asked, and it's good to talk with you once more. That's a very good question. Building a foundation is something we've handled well; our balance sheet is stronger now. Our resources are more than sufficient, and our hope is to deploy them effectively. We hold $12 million in cash, and on top of that there's a $7 million line of credit we haven't drawn on; beyond that, those resources can be leveraged further. So a considerable investment is going into our sales and marketing push — not only the hours people are putting in, but we're also planning to bring on more resources soon. Regarding prospects, I can say they look quite strong. That said, as you're aware, lead cycles run long in this industry, and we have different prospects sitting at different points along that sales cycle; and we tend to be rather hesitant about discussing future expectations, so to speak, or future arrangements. I'm happy that earlier in the year we announced our joint venture located in Puebla, Mexico; that stands as another demonstration of our broader product lineup. What we're supplying is a linear accelerator from Elekta — it isn't a Gamma Knife, it's a linear accelerator. With that wider range of products, we're seeing ourselves pick up some momentum. On geography, we're examining possibilities in both the United States and abroad. Wherever potential appears, we go after it; and what we're coming to realize is that, in my view, more resources really are needed for our sales and marketing push. So Tony, I hope that gives you an answer with a reasonable level of confidence.
Tony Kamin
analystAbsolutely. I want to ask a couple of additional follow-ups that are somewhat connected. First, considering the proton beams or the fact that this is becoming a more mature sector than before, are you aware of any ongoing studies regarding how effective it is compared with competing products? And second, when you examine the entire field of proton beams and LINACs and all the rest, are there any movements where one or another is becoming more favored, or any other types of technological changes that you're monitoring and consider significant?
Ray Stachowiak
executiveI'd want Craig to weigh in on this. However, prior to handing things to Craig, I'd like to speak generally. We continue to observe favorable progress in proton therapy treatments, and the clinical sides of those treatments are quite encouraging. Another general point I'd like to raise is that innovation keeps happening at a high rate in this area, not only with protons but with photon technology as well. And we're likely better positioned than at any previous time to stay current with those emerging technologies, which allows us to assess those possibilities. Craig, would you care to add anything?
Craig Tagawa
executiveAbsolutely, Ray — thanks. What I'd say is this: when you look at the top cancer centers across the U.S., a growing number of them are fully getting behind proton therapy and building it into how they treat patients. That, I believe, speaks volumes about whether this is an essential technology for leading cancer centers — it's evidence of exactly that. On top of that, we're beginning to see certain large nonacademic cancer centers adopt proton therapy too, and my sense is that this movement will keep going. There's another shift we've picked up on as well: with the MR/LINACs Ray has mentioned previously, an increasing number of sites handling a substantial volume of patients are now evaluating this technology and expressing interest in having it. When you consider these two categories of technology, the capital expense involved is significant in each case; so my view is that these are precisely the kinds of technologies where American Shared is able to work alongside hospitals and take on a portion of the risk together with them — whether that's risk around allocating capital, any reimbursement risk they may perceive, or risk tied to patient volume. Before signing any contracts related to these two technologies, we conduct thorough due diligence together with the hospital. That said, my feeling is that both of these technologies hold considerable promise — not only when it comes to uptake among major cancer centers, but also in the area where American Shared is positioned to take part.
Tony Kamin
analystAlright, that clears things up nicely. Let me ask one last thing — I simply can't recall how this works. I understand that when it comes to proton beam equipment makers, you're fairly neutral these days; but are there still deposits sitting there that could be applied toward Mevion units, the ones I recall you placed money on some time back?
Ray Stachowiak
executiveThat's right, Tony. Those deposits got written off the balance sheet back in Q4 of 2020. That said — should we move forward with buying from Mevion, the funds remain credited to us on Mevion's books. The reason we took those assets off in Q4 of 2020 was that our visibility into getting any value back from that deposit wasn't solid. So that puts us in a favorable spot. Regarding our proton investments, we don't favor any particular OEM; yet were we to go ahead with Mevion, those deposits would still be available to us.
Ray Stachowiak
executiveOkay. Thanks, Sarah, and thanks to all of you for being with us today. We've now had 4 quarters in a row with better results. Our foundation is solid, and we have considerable resources at our disposal. We think AMS is headed down the road I've talked about a number of times on these calls — one of lasting growth and profitability. We're eager to talk with you once more on our call for the third quarter in mid-November. If anything comes up before then, don't hesitate to reach out to us directly. Take care, and stay safe. Goodbye.
Operator
operatorThat brings this conference to a close. We appreciate your participation in today's presentation. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.